Connect Biopharma Holdings Earnings Call Transcripts
Fiscal Year 2026
-
Rademikibart IV showed rapid, robust FEV1 improvements in asthma and COPD, with effects seen within 15 minutes and sustained for 29 days, outperforming existing therapies. Atopic dermatitis results demonstrated high long-term efficacy and low conjunctivitis rates. Top-line results from ongoing acute exacerbation studies are expected mid-year.
-
A next-generation IL-4 receptor antibody is advancing in acute asthma and COPD, with rapid onset and unique efficacy and safety profiles. Phase II data and IV study results are expected soon, while a China partnership could yield significant milestones and global expansion opportunities.
-
Rademikibart, a next-generation IL-4Rα antibody, is advancing in acute and chronic asthma and COPD, showing rapid efficacy and a differentiated safety profile. Acute studies are expected to drive both market adoption and regulatory progress, with key data and milestones anticipated midyear.
Fiscal Year 2025
-
A next-generation IL-4 receptor alpha antibody is being developed for rapid-onset treatment of acute asthma and COPD, targeting a large unmet need in acute care. Phase 2 global trials are underway, with key data expected in the first half of next year, and regulatory engagement planned soon after.
-
Rademikibart is positioned as a first-in-class biologic for acute asthma and COPD, with rapid efficacy, a favorable safety profile, and no direct competitors for acute treatment. Phase II data is expected in the first half of next year, and the company is well-funded with strong partnership prospects.
-
Connect has transformed into a U.S.-focused biotech, advancing rademikibart for acute asthma exacerbations with rapid onset and a differentiated safety profile. The acute indication is positioned as a gateway to chronic use, with strong clinician interest and a solid cash runway into 2027.
-
Leadership refocused operations to the U.S. and advanced rademikibart for acute asthma and COPD, targeting a large unmet market. Phase II trials are underway with top-line data expected next year, and financials support ongoing development.
-
A new management team is advancing rademikibart, a next-gen IL-4 antibody, for acute asthma and COPD, targeting a large, untapped market with rapid-onset efficacy and a differentiated safety profile. Acute and chronic studies are underway, with data expected next year and a strong cash runway into 2027.
-
A new management team is driving a U.S.-centric strategy focused on rademikibart for acute asthma and COPD, with rapid clinical benefits and a differentiated safety profile. Acute indications could unlock a $5B+ market, with phase 2 results expected in the first half of next year.
-
Leadership has refocused on rademikibart, a next-gen IL-4 antibody showing rapid, significant airway improvement and a favorable safety profile. Phase 2 trials for acute exacerbations in asthma and COPD will begin soon, targeting a large unmet market with data expected next year.
-
Management overhaul and a U.S.-centric shift set the stage for rapid phase 2 trials of rademikibart in acute asthma and COPD. The drug targets a large, unmet market with unique acute indications, aiming for fast enrollment and data by next year.